Status:

COMPLETED

MARS - Monitored Atherosclerosis Regression Study

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Atherosclerosis

Coronary Artery Disease

Eligibility:

All Genders

21-67 years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce r...

Detailed Description

Two conceptual advances occurring in the 1980's made it possible to test the hypothesis that significant alterations in serum lipoproteins can substantially reduce atherosclerosis progression or even ...

Eligibility Criteria

Inclusion

  • Angiography within 17 weeks of randomization showing patient is at high risk for coronary artery disease but not a candidate for coronary artery graft surgery
  • Men and women ages 21 through 67 years
  • Mean plasma cholesterol levels from the first two screening visits in the range of 190 to 270 mg/dL
  • Smokers are admitted, but encouraged to stop smoking tobacco

Exclusion

  • Premenopausal women unless surgically sterilized
  • Hypertension, diabetes, thyroid disease, liver dysfunction, renal insufficiency, congestive heart failure, major arrhythmia, left ventricular conduction defects
  • Physical impairment that may interfere with participation
  • Life threatening disease with high likelihood of disability or death during the trial period
  • Use of hydralazine, guanethidine, lipid-lowering drugs, estrogens, steroids, amphetamines, antibiotics, theophylline, acetaminophen (average daily use greater than ten grains), other drugs as determined by the principle investigator
  • Vitamins A or D in doses greater than the Recommended Daily Allowance (RDA)
  • Alcohol abuse
  • Nutritional supplements high in cholesterol content
  • Chelation therapy
  • Psychosocial situations which make completion of the study unlikely
  • Hypersensitivity to any component of the study medication

Key Trial Info

Start Date :

June 1 1985

Trial Type :

INTERVENTIONAL

End Date :

February 1 1992

Estimated Enrollment :

270 Patients enrolled

Trial Details

Trial ID

NCT00116870

Start Date

June 1 1985

End Date

February 1 1992

Last Update

December 11 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine

Los Angeles, California, United States, 90033